Form 8-K - Current report:
SEC Accession No. 0001213900-23-063832
Filing Date
2023-08-07
Accepted
2023-08-07 08:00:33
Documents
14
Period of Report
2023-08-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea182142-8k_abvcbio.htm   iXBRL 8-K 24311
2 PRESS RELEASE, DATED AUGUST 7, 2023 ea182142ex99-1_abvcbio.htm EX-99.1 28500
3 GRAPHIC ex99-1_001.jpg GRAPHIC 5654
  Complete submission text file 0001213900-23-063832.txt   241084

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE abvc-20230807.xsd EX-101.SCH 3021
5 XBRL LABEL FILE abvc-20230807_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE abvc-20230807_pre.xml EX-101.PRE 22363
8 EXTRACTED XBRL INSTANCE DOCUMENT ea182142-8k_abvcbio_htm.xml XML 3216
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

EIN.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 231145702
SIC: 2834 Pharmaceutical Preparations